WO2001040277A3 - Glycoproteines a hydrates de carbone amines - Google Patents

Glycoproteines a hydrates de carbone amines Download PDF

Info

Publication number
WO2001040277A3
WO2001040277A3 PCT/US2000/033075 US0033075W WO0140277A3 WO 2001040277 A3 WO2001040277 A3 WO 2001040277A3 US 0033075 W US0033075 W US 0033075W WO 0140277 A3 WO0140277 A3 WO 0140277A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbohydrate
aminated
subject
glycoproteins
relates
Prior art date
Application number
PCT/US2000/033075
Other languages
English (en)
Other versions
WO2001040277A2 (fr
Inventor
Leslie W Fisette
Bernard Malfroy-Camine
Original Assignee
Eukarion Inc
Leslie W Fisette
Bernard Malfroy-Camine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eukarion Inc, Leslie W Fisette, Bernard Malfroy-Camine filed Critical Eukarion Inc
Priority to AU20642/01A priority Critical patent/AU2064201A/en
Publication of WO2001040277A2 publication Critical patent/WO2001040277A2/fr
Publication of WO2001040277A3 publication Critical patent/WO2001040277A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des glycoprotéines à hydrates de carbone aminés (des anticorps, des facteurs de croissance, par exemple) comprenant un fragment diamine lié par covalence à un fragment d'hydrate de carbone par liaison simple ou double formée entre un atome d'azote dudit fragment diamine et un atome de carbone d'un fragment de l'hydrate de carbone oxydé de ladite glycoprotéine, et des compositions pharmaceutiques renfermant ces glycoprotéines à hydrates de carbone aminés. Les protéines à hydrates de carbone aminés de l'invention peuvent traverser la membrane cellulaire de cellules vivantes et être assimilées par les organes et les tissus plus rapidement et dans une plus grande mesure que les glycoprotéines natives après administration intravasculaire. L'invention concerne également une méthode destinée à administrer une glycoprotéine à hydrates de carbone aminés à une cellule de façon intracellulaire et une méthode destinées à administrer une glycoprotéine à hydrates de carbone aminés à un organe ou à un tissu de façon transvasculaire. L'invention concerne également une méthode destinée à inhiber la réplication d'un virus chez un sujet, consistant à administrer au sujet un anticorps à hydrates de carbone aminés inhibant la réplication du virus en se liant à une protéine nécessaire à la réplication par exemple. L'invention concerne également une méthode destinées au traitement d'un sujet infecté par un parasite intracellulaire, consistant à administrer au sujet un anticorps à hydrates de carbone aminés inhibant la prolifération et/ou la propagation du parasite en se liant à une protéine agissant sur la prolifération ou la propagation du parasite par exemple. L'invention concerne également une méthode destinée au traitement d'un sujet atteint d'une tumeur, consistant à administrer au sujet un anticorps à hydrates de carbone aminés dirigé contre un antigène tumoral.
PCT/US2000/033075 1999-12-06 2000-12-06 Glycoproteines a hydrates de carbone amines WO2001040277A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20642/01A AU2064201A (en) 1999-12-06 2000-12-06 Carbohydrate-aminated glycoproteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45559899A 1999-12-06 1999-12-06
US09/455,598 1999-12-06

Publications (2)

Publication Number Publication Date
WO2001040277A2 WO2001040277A2 (fr) 2001-06-07
WO2001040277A3 true WO2001040277A3 (fr) 2002-06-27

Family

ID=23809488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033075 WO2001040277A2 (fr) 1999-12-06 2000-12-06 Glycoproteines a hydrates de carbone amines

Country Status (2)

Country Link
AU (1) AU2064201A (fr)
WO (1) WO2001040277A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
EP3150702B1 (fr) 2011-06-19 2021-05-19 DNA Genotek, Inc. Dispositifs, solutions et procédés de collecte d'échantillons
RU2016141811A (ru) 2014-04-10 2018-05-10 ДиЭнЭй ГЕНОТЕК ИНК. Способ и система для лизиса микроорганизмов с применением периодатов

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237479A1 (de) * 1992-11-06 1994-05-11 Behringwerke Ag Verfahren zur Herstellung von Konjugaten aus einem spezifischen Bindungspartner und einem kohlenhydrathaltigen Protein
WO1996029094A1 (fr) * 1995-03-22 1996-09-26 Andrew Lees Preparation de produits de recombinaison immunogenes au moyen d'hydrates de carbone solubles actives par l'intermediaire de reactifs organiques de cyanylation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237479A1 (de) * 1992-11-06 1994-05-11 Behringwerke Ag Verfahren zur Herstellung von Konjugaten aus einem spezifischen Bindungspartner und einem kohlenhydrathaltigen Protein
WO1996029094A1 (fr) * 1995-03-22 1996-09-26 Andrew Lees Preparation de produits de recombinaison immunogenes au moyen d'hydrates de carbone solubles actives par l'intermediaire de reactifs organiques de cyanylation

Also Published As

Publication number Publication date
WO2001040277A2 (fr) 2001-06-07
AU2064201A (en) 2001-06-12

Similar Documents

Publication Publication Date Title
Samaniego et al. Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice.
Pinsky et al. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta.
DE69631605T2 (de) Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen
JPH05504554A (ja) 免疫強化を促進するための方法と組成物
WO2005097202A3 (fr) Nouvelle utilisation et methode
JP2008526749A (ja) 自己アセンブリするペプチドナノファイバーを用いたｐｄｇｆの徐放性の送達
ZA200410287B (en) Compositions and methods for modulating physiologyof epithelial junctional adhesion molecules for e nhanced mucosal delivery of therapeutic compounds.
EP1027073A2 (fr) Effets renforces pour therapeutique associee a l'haptene
Human et al. Inflammatory and immune processes: the neglected villain of bioprosthetic degeneration?
ES2711669A1 (es) Sistemas de liberacion de farmacos de acido polisialico y metodos
Miettinen et al. Leiomyosarcoma of the mandible: diagnosis as aided by immunohistochemical demonstration of desmin and laminin
Wang et al. Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity
Su et al. New opportunities for immunomodulation of the tumour microenvironment using chemical tools
EP0374207B1 (fr) Medicament pour le traitement du cancer, du sida et des maladies virales
Vesely et al. Urodilatin and four cardiac hormones decrease human renal carcinoma cell numbers
US10925960B2 (en) Antigen delivery system
EP1455766B1 (fr) Conjugués de polymères/peptides thymosine alpha 1
WO2001040277A3 (fr) Glycoproteines a hydrates de carbone amines
JPH06157336A (ja) 腫瘍性疾病治療用細胞毒性薬物複合体
JP5706163B2 (ja) 線維症および肝疾患の治療
KR101761092B1 (ko) 췌도 세포 이식용 조성물
GB0102145D0 (en) Substances
KR102169663B1 (ko) 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물
CA2451479A1 (fr) Procedes permettant d'induire une reaction immunitaire avec un rapport th1 :th2 eleve par induction intracellulaire de nfkappab
Falk et al. Effective antitumor immunity following elimination of suppressor T cell function

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP